22-23834152-G-A
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM1PM2PM5PP2PP3_ModeratePP5
The NM_003073.5(SMARCB1):c.1130G>A(p.Arg377His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000125 in 1,593,918 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R377G) has been classified as Likely pathogenic.
Frequency
Consequence
NM_003073.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SMARCB1 | NM_003073.5 | c.1130G>A | p.Arg377His | missense_variant | 9/9 | ENST00000644036.2 | |
SMARCB1 | NM_001362877.2 | c.1184G>A | p.Arg395His | missense_variant | 9/9 | ||
SMARCB1 | NM_001317946.2 | c.1157G>A | p.Arg386His | missense_variant | 9/9 | ||
SMARCB1 | NM_001007468.3 | c.1103G>A | p.Arg368His | missense_variant | 9/9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SMARCB1 | ENST00000644036.2 | c.1130G>A | p.Arg377His | missense_variant | 9/9 | NM_003073.5 | A1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152244Hom.: 0 Cov.: 33
GnomAD4 exome AF: 6.94e-7 AC: 1AN: 1441674Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 715478
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152244Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74374
ClinVar
Submissions by phenotype
Intellectual disability, autosomal dominant 15 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 18, 2012 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 29, 2020 | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed in individual(s) with clinical features of Coffin-Siris syndrome (PMID: 22426308, 25169651). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 30203). This variant is not present in population databases (ExAC no frequency). This sequence change replaces arginine with histidine at codon 377 of the SMARCB1 protein (p.Arg377His). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and histidine. - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 31, 2018 | PLEASE SELECT CORRECT RD FOR YOUR CASE - EDIT IN THE REPORT VUS (CANCER) The p.R377H variant (also known as c.1130G>A), located in coding exon 9 of the SMARCB1 gene, results from a G to A substitution at nucleotide position 1130. The arginine at codon 377 is replaced by histidine, an amino acid with highly similar properties. This variant has been reported in patients with Coffin-Siris syndrome and DOORS syndrome (Tsurusaki Y et al. Nat. Genet. 2012 Mar;44:376-8; Kosho T et al. Am. J. Med. Genet. A. 2013 Jun;161A:1221-37; Campeau PM et al. Am. J. Med. Genet. C Semin. Med. Genet. 2014 Sep;166C:327-32; Kosho T et al. Am. J Med. Genet. C Semin. Med. Genet. 2014 Sep;166C:262-75). It has also been identified as a somatic variant in multiple tumor types including meningiomas (Schmitz U et al. Br. J. Cancer. 2001 Jan;84:199-201; Torres-Martín M et al. Cancer Genet. 2015 Jun;208:327-32; Tang M et al. Oncotarget. 2017 Mar;8:17070-17080), gastric cancers (Kim JG et al. Cancer Lett. 2013 Mar;330:33-40; Takeshima H et al. Cancer Lett., 2015 Feb;357:328-338), odontogenic tumors (Brown NA et al. Clin. Cancer Res. 2014 Nov;20:5517-26), sarcomas (Andersson C et al. Cancer Genet, 2016 Apr;209:154-60), and schwannomas (Paganini I et al. J. Neurooncol. 2018 Mar;137:33-38). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear for hereditary cancer predisposition . VLP (NEURO) The p.R377H variant (also known as c.1130G>A), located in coding exon 9 of the SMARCB1 gene, results from a G to A substitution at nucleotide position 1130. The arginine at codon 377 is replaced by histidine, an amino acid with highly similar properties. This variant has been detected de novo in an individual with Coffin-Siris syndrome (Tsurusaki Y et al. Nat. Genet. 2012 Mar;44:376-8; Kosho T et al. Am. J. Med. Genet. A. 2013 Jun;161A:1221-37; Kosho T et al. Am. J Med. Genet. C Semin. Med. Genet. 2014 Sep;166C:262-75). This variant was also detected de novo in two individuals with DOORS syndrome (Campeau PM et al. Am. J. Med. Genet. C Semin. Med. Genet. 2014 Sep;166C:327-32). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at